Recent product developments
Pfizer (PFE) is focused on the development of new products and the expansion of its market reach with new and existing products to strengthen its Innovative Health business.
In October 2017, the FDA (US Food and Drug Administration) approved Lyrica CR (pregabalin), a once-daily extended-release tablet for the management of postherpatic neuralgia and neuropathic pain associated with diabetic peripheral neuropathy. The drug was not approved for the management of fibromyalgia.
In September 2017, the FDA approved Mylotarg (gemtuzumab ozogamicin) for the treatment of patients with CD33-positive acute myeloid leukemia.
In September 2017, the European Commission approved Bavencio (avelumab), a drug co-developed by Pfizer and Merck KGaA, as a monotherapy for the treatment of patients with metastatic Merkel cell carcinoma.
Other key developments
In September 2017, the Japanese Ministry of Health, Labor, and Welfare or MHLW approved Ibrance for the treatment of HR+/HER2- breast cancer.
In August 2017, the FDA approved Besponsa (inotuzumab ozogamicin) for the treatment of patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
In August 2017, the FDA accepted the supplemental New Drug Application for Bosulif (bosutinib) and granted priority review.
Notably, the PowerShares Dynamic Pharmaceuticals ETF (PJP) has 4.8% of its total assets in Pfizer (PFE). PJP also has 5.0% in Celgene (CELG), 4.7% in Johnson & Johnson (JNJ), and 5.3% in Gilead Sciences (GILD).